| Chapter title |
Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.
|
|---|---|
| Chapter number | 431 |
| Book title |
Cancer Vaccines
|
| Published in |
Current topics in microbiology and immunology, February 2015
|
| DOI | 10.1007/82_2015_431 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-923909-5, 978-3-31-923910-1
|
| Authors |
Kimberly A Kraynyak, Angela Bodles-Brakhop, Mark Bagarazzi, Kimberly A. Kraynyak |
| Abstract |
Cancer is a worldwide leading cause of death, and current conventional therapies are limited. The search for alternative preventive or therapeutic solutions is critical if we are going to improve outcomes for patients. The potential for DNA vaccines in the treatment and prevention of cancer has gained great momentum since initial findings almost 2 decades ago that revealed that genetically engineered DNA can elicit an immune response. The combination of adjuvants and an effective delivery method such as electroporation is overcoming past setbacks for naked plasmid DNA (pDNA) as a potential preventive or therapeutic approach to cancer in large animals and humans. In this chapter, we aim to focus on the novel advances in recent years for DNA cancer vaccines, current preclinical data, and the importance of adjuvants and electroporation with emphasis on prostate, melanoma, and cervical cancer. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 4% |
| India | 1 | 4% |
| Unknown | 25 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 22% |
| Student > Ph. D. Student | 5 | 19% |
| Other | 4 | 15% |
| Student > Master | 3 | 11% |
| Student > Doctoral Student | 2 | 7% |
| Other | 3 | 11% |
| Unknown | 4 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Immunology and Microbiology | 4 | 15% |
| Agricultural and Biological Sciences | 3 | 11% |
| Medicine and Dentistry | 3 | 11% |
| Computer Science | 2 | 7% |
| Other | 4 | 15% |
| Unknown | 7 | 26% |